Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 39

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 39
---
)
with the Medical Technology Enterprise Consortium (“MTEC”), pursuant to which we received a $15.0 million award and
entered into a multi-year program administered by the U.S. Department of Defense (the “DoD”) through MTEC and managed by
the Naval Medical Research Command – Naval Advanced Medical Development with funding from the Defense Health Agency and Joint
Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3
million to $16.3 million and extend the term into the second half of 2024. On July 29, 2024, the MTEC Agreement was modified to
increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. On April 29, 2025, we received $4.65 million of additional non-dilutive award funding through MTEC, thereby increasing the total MTEC award to $26.2 million, and the MTEC Agreement was modified to extend the term to September 30, 2025. On July 2, 2025, the MTEC Agreement was modified to extend the term to March 31, 2026.We are using the award to partially fund a
Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled dose escalation study to assess the safety, tolerability and
efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with S. aureus(the
“diSArm” study) and to support activities required for an end-of-Phase 2 meeting with the FDA.

On
November 17, 2021, we announced that we had received approval from the FDA to proceed with our IND application for AP-SA02.

On May 19, 2025, we announced positive topline data from the Phase 1b/2a diSArm study of intravenously administered AP-SA02 in complicatedS. aureusbacteremia.The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter,
randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous
AP-SA02 in addition to best available antibiotic therapy (BAT) compared to BAT alone (placebo) for the treatment of adults